Terms ending in 2032
Interpace Diagnostics Corporation
Every in-force patent on Interpace Diagnostics Corporation's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,644,241 | Methods and Compositions Involving MIR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease In force · High confidence | Interpace Diagnostics, LLC | In force | High confidence | |
| US 10,655,184 | Methods and Compositions Involving MIR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease In force · High confidence | Interpace Diagnostics, LLC | In force | High confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.